Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer - PubMed
3 days ago
- #Non-Small Cell Lung Cancer
- #EGFR-mutated
- #Patient-Reported Outcomes
- FLAURA2 study compared osimertinib plus platinum-pemetrexed induction followed by maintenance versus osimertinib alone in EGFR-mutated advanced NSCLC.
- Combination therapy improved progression-free survival (HR, 0.62; P < 0.001) but had higher grade ≥3 adverse events during induction.
- Patient-reported outcomes (PROs) showed intermediate-to-high baseline functioning and global health status (GHS/QoL) with mild symptoms.
- Non-clinically meaningful improvements in GHS/QoL and physical function were observed in both treatment arms.
- Clinically meaningful improvements in cough were seen with both combination and monotherapy from Week 5.
- Combination therapy showed non-clinically meaningful deteriorations in fatigue and appetite loss during induction.
- Both treatments were similarly well tolerated based on PRO-CTCAE assessments.
- Osimertinib monotherapy and combination therapy had non-clinically meaningful impacts on HRQoL in mildly symptomatic patients.